EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life

Uwe Reuter iD, Axel Heinze, Astrid Gendolla, Christian Sieder, Christian Hentschke

European Journal of Neurology · 2024-12 · 31 (12)

DOI: 10.1111/ene.16437 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, online erschienen am 12.08.2024. Verfasst von Uwe Reuter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Charite Universitatsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Topiramate, Migraine Disorders, Antibodies, Monoclonal, Humanized, Quality of Life. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose HER‐MES was the first head‐to‐head study of erenumab against topiramate (standard of care). This post hoc analysis of the HER‐MES study evaluated the effect of erenumab versus topiramate on patient‐reported outcomes at week 24.

Methods

Adult patients with episodic or chronic migraine ( n = 777) were randomized (1:1) to monthly subcutaneous erenumab ( n = 389) or daily oral topiramate ( n = 388). Migraine‐related disability, as measured by the Headache Impact Test 6 (HIT‐6) and Short Form 36 Health Survey version 2 (SF‐36v2), was analysed in the entire study cohort and true completers.

Results

In the erenumab group (vs. topiramate), significant improvements were reported in Headache Impact Test 6 total scores (composite populations, −10.88 vs. −7.72; true completers, −11.92 vs. −10.61) and a higher proportion of patients achieved a ≥5‐point reduction from baseline with erenumab (composite populations, 72.2% vs. 53.9%; true completers, 79.64% vs. 71.43%). The adjusted mean change from baseline in the SF‐36v2 score was greater with erenumab for both physical component summary (composite population, 5.48 vs. 3.63; true completers, 5.95 vs. 5.23) and mental component summary (composite populations, 1.00 vs. −1.18; true completers, 1.74 vs. −0.33). A higher proportion of patients on erenumab versus topiramate had a ≥5‐point improvement in SF‐36v2 for the physical component summary (composite populations, 47.7% vs. 37.4%; true completers, 52.1% vs. 48.9%) and mental component summary (composite populations, 25.3% vs. 16.8%; true completers, 27.3% vs. 17.7%).

Conclusions

This post hoc analysis demonstrated that patients treated with erenumab had significant improvements in headache impact and quality of life as measured by patient‐reported outcomes versus patients treated with topiramate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TopiramateMigraine DisordersAntibodies, Monoclonal, HumanizedQuality of LifeHumansFemaleAdultMaleMiddle AgedTreatment OutcomeFructoseCalcitonin Gene-Related Peptide Receptor AntagonistsDouble-Blind MethodPatient Reported Outcome Measures

Stichwörter der Autor:innen

calcitonin gene‐related peptideerenumabmigraine‐related disabilitypatient‐reported outcomesquality of life

Substanzen

TopiramateAntibodies, Monoclonal, HumanizederenumabFructoseCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Department of Neurology, Charite Universitatsmedizin Berlin, Berlin, Germany.
  • Universitatsmedizin Greifswald, Greifswald, Germany.
  • Schmerzklinik Kiel, Migraine and Headache Center, Kiel, Germany.
  • Praxis Gendolla, Essen, Germany.
  • Novartis Pharma GmbH, Nuremberg, Germany.

ORCID-Profile: Uwe Reuter

Förderung

  • Novartis Pharma

Zitieren

APA

Reuter, U., Heinze, A., Gendolla, A., Sieder, C., & Hentschke, C. (2024). Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life. European Journal of Neurology, 31(12). https://doi.org/10.1111/ene.16437

Vancouver

Reuter U, Heinze A, Gendolla A, Sieder C, Hentschke C. Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life. European Journal of Neurology. 2024;31(12). doi:10.1111/ene.16437

BibTeX
@article{Reuter2024,
  author = {Reuter, Uwe and Heinze, Axel and Gendolla, Astrid and Sieder, Christian and Hentschke, Christian},
  title = {Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {12},
  doi = {10.1111/ene.16437}
}
Kostenlos starten →